Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Rhode Island Hospital
mi
from
Providence, RI
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Avera Research Institute
mi
from
Sioux Falls, SD
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Avera Research Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated:  11/3/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol
Status: Enrolling
Updated: 11/3/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Lahey Hospital & Medical Center
mi
from
Burlington, CA
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Lahey Hospital & Medical Center
mi
from
Burlington, CA
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Miami Hospital and Clinics
mi
from
Miami, FL
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Miami Hospital and Clinics
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Ohio State University, Martha Morehouse Medical Plaza
mi
from
Columbus, OH
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Ohio State University, Martha Morehouse Medical Plaza
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
Status: Enrolling
Updated:  11/3/2015
University of Michigan
mi
from
Ann Arbor, MI
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
Status: Enrolling
Updated: 11/3/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/3/2015
Cancer Research Center. University of Chicago Hospitals
mi
from
Chicago, IL
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/3/2015
Cancer Research Center. University of Chicago Hospitals
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/3/2015
Vall d'Hebron University Hospital
mi
from
Barcelona,
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/3/2015
Vall d'Hebron University Hospital
mi
from
Barcelona,
Click here to add this to my saved trials
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated:  11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated: 11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Click here to add this to my saved trials
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine
Status: Enrolling
Updated:  11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine
Status: Enrolling
Updated: 11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine
Status: Enrolling
Updated:  11/4/2015
South Pasadena Cancer Center
mi
from
Pasadena, CA
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine
Status: Enrolling
Updated: 11/4/2015
South Pasadena Cancer Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol
Status: Enrolling
Updated:  11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol
Status: Enrolling
Updated: 11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
University of Rochester
mi
from
Rochester, NY
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Birmingham, AL
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Altanta, GA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Altanta, GA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Boston, MA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
New York, NY
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Durham, NC
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Columbus, OH
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Philadelphia, PA
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceutical Investigative Site
mi
from
Houston, TX
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceutical Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated:  11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Cordoba,
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Status: Enrolling
Updated: 11/4/2015
Synta Pharmaceuticals Investigative Site
mi
from
Cordoba,
Click here to add this to my saved trials
A Study of Mitomycin C, Irinotecan, and Cetuximab
A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/4/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Mitomycin C, Irinotecan, and Cetuximab
A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/4/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  11/4/2015
Johns Hopkins University
mi
from
Baltimore, MD
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 11/4/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  11/4/2015
Ohio State University
mi
from
Columbus, OH
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 11/4/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  11/4/2015
Princess Margaret Hospital
mi
from
Toronto,
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 11/4/2015
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
Status: Enrolling
Updated:  11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
Status: Enrolling
Updated: 11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Palliative Care for Quality of Life and Symptom Concerns in Late Stage Lung Cancer
Status: Enrolling
Updated:  11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Palliative Care for Quality of Life and Symptom Concerns in Late Stage Lung Cancer
Status: Enrolling
Updated: 11/4/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated:  11/5/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Status: Enrolling
Updated: 11/5/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated:  11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25
Status: Enrolling
Updated: 11/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Arizona Clinical Research Center
mi
from
Tucson, AZ
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
Clearview Cancer Institute
mi
from
Huntsville, AL
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  11/5/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 11/5/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials